Literature DB >> 10813370

Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently.

R H Schwinger1, M Pietsch, K Frank, K Brixius.   

Abstract

The mode of action of Crataegus extracts in the treatment of heart failure is still under examination. WS 1442, a standardized special extract from Crataegus leaves with flowers, exerts direct positive inotropic effects. This study was designed to investigate the mode of inotropic action of WS 1442 in human myocardium from patients with congestive heart failure (left ventricular myocardium from explanted hearts; NYHA IV, n = 8) as well as in nonfailing controls (right auricular trabeculae from patients with coronary heart disease, n = 8). WS 1442 effectively displaced specifically bound 3H-ouabain but did not influence the activity of adenylate cyclase [control, + Gpp(NH)p (10(-4) microM) 3,500 pmol cyclic adenosine monophosphate (cAMP)/20 min). In isolated left ventricular papillary muscle strips, WS 1442 significantly increased the force of contraction [basal, 1.8+/-0.2 mN; WS 1442 (50 microg/ml), 2.4+/-0.1 mN (130%)] and improved the frequency-dependent force generation (0.5 vs. 2.5 Hz: control, +0.1+/-0.01 mN; WS 1442, +0.9+/-0.3 mN) even in failing human myocardium. In fura-2-loaded muscle strips (right atrial trabeculae), WS 1442 increased both the Ca2+-transient and force generation. These effects also were observed in the lipophilic ethyl acetate-soluble fraction A, enriched in flavone derivatives. In conclusion, these findings suggest a pharmacologic mechanism of WS 1442 similar to the cAMP-independent positive inotropic action of cardiac glycosides. In addition, WS 1442 improves the force-frequency relation in failing human myocardium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813370     DOI: 10.1097/00005344-200005000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2007: 2L-Registry, Kardio-Pro, EVER, AFFECT, VTACH, ARTS II, OPTAMI, PEPCAD I, PEPCAD II, GERSHWIN, SPICE, FIX-CHF and CREDIT.

Authors:  Stephan Rosenkranz; Lars S Maier; Christoph Maack; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2007-06-11       Impact factor: 5.460

Review 2.  Medicinal Herbs in the Relief of Neurological, Cardiovascular, and Respiratory Symptoms after COVID-19 Infection A Literature Review.

Authors:  Joanna Nawrot; Justyna Gornowicz-Porowska; Jaromir Budzianowski; Gerard Nowak; Grzegorz Schroeder; Joanna Kurczewska
Journal:  Cells       Date:  2022-06-11       Impact factor: 7.666

Review 3.  Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach.

Authors:  Jie Wang; Xingjiang Xiong; Bo Feng
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-29       Impact factor: 2.629

Review 4.  Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review.

Authors:  Christian J F Holubarsch; Wilson S Colucci; Jaan Eha
Journal:  Am J Cardiovasc Drugs       Date:  2018-02       Impact factor: 3.571

Review 5.  Polyphenolic profile and biological activity of Chinese hawthorn (Crataegus pinnatifida BUNGE) fruits.

Authors:  Tunde Jurikova; Jiri Sochor; Otakar Rop; Jiri Mlcek; Stefan Balla; Ladislav Szekeres; Vojtech Adam; Rene Kizek
Journal:  Molecules       Date:  2012-12-06       Impact factor: 4.411

6.  Procyanidin C1 from Viola odorata L. inhibits Na+,K+-ATPase.

Authors:  Tomas Heger; Marek Zatloukal; Martin Kubala; Miroslav Strnad; Jiri Gruz
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

7.  The combination of catechin and epicatechin callate from Fructus Crataegi potentiates beta-lactam antibiotics against methicillin-resistant staphylococcus aureus (MRSA) in vitro and in vivo.

Authors:  Rongxin Qin; Kangkang Xiao; Bin Li; Weiwei Jiang; Wei Peng; Jiang Zheng; Hong Zhou
Journal:  Int J Mol Sci       Date:  2013-01-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.